Dipyridamole in the Management of Severe Heparin-associated Thrombocytopenia
作者:
AlA. K.,
GaderA. M. A.,
期刊:
Platelets
(Taylor Available online 1993)
卷期:
Volume 4,
issue 2
页码: 67-71
ISSN:0953-7104
年代: 1993
DOI:10.3109/09537109309013198
出版商: Taylor&Francis
数据来源: Taylor
摘要:
Severe heparin-associated thrombocytopenia (SHAT) is a rare, life-threatening condition. The aim of this prospective pilot study was to determine the safety and efficacy of dipyridamole-heparin infusion (DHI) in the management of the condition. We studied 6 patients (4 males and 2 females) aged 28 to 80 years (mean 50.5±14.2) with deep venous thrombosis and/or pulmonary embolism who developed SHAT a few days following heparin therapy. Heparin-dependent platelet aggregating factor was demonstrated ex vivo in the plasma of 4 patients. 240–300 mg of dipyridamole/day (4 mg/kg/day) was mixed with heparin in the same bag and given as a continuous intravenous infusion. Anticoagulation was continued successfully along with significant platelet recovery over a few days. This regimen was without side-effects. We conclude that DHI may provide an effective therapy for patients with SHAT.
点击下载:
PDF (543KB)
返 回